Valuation: BioNTech SE

Market Cap 21.55B 24.08B 20.09B 18.22B 34.37B 2,301B 34.59B 241B 94.52B 1,188B 90.44B 88.43B 3,822B P/E 2026 *
-14.6x
P/E 2027 * -15.7x
Enterprise Value 10.46B 11.69B 9.75B 8.85B 16.69B 1,117B 16.79B 117B 45.88B 577B 43.9B 42.93B 1,855B EV / Sales 2026 *
5.85x
EV / Sales 2027 * 6.61x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.16%
1 week-1.84%
Current month-2.50%
1 month-0.92%
3 months+4.75%
6 months+0.36%
Current year+0.67%
1 week 91.64
Extreme 91.64
98.6
1 month 91.64
Extreme 91.64
103
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 61 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 56 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 Sell

Chief Executive Officer

-24,000 0.0099%
10/6/26 Sell

Chief Executive Officer

-21,000 0.0087%
10/2/26 Sell

Chief Executive Officer

-17,000 0.0070%
Change 5-day change 1-year change 3-year change Capi.($)
-1.16%-1.84% - - 24.36B
Average -1.16%
Weighted average by Cap. -1.16%

Financials

2026 *2027 *
Net sales 1.79B 2B 1.67B 1.51B 2.85B 191B 2.87B 20.02B 7.84B 98.48B 7.5B 7.33B 317B 1.8B 2.01B 1.67B 1.52B 2.86B 192B 2.88B 20.12B 7.88B 98.99B 7.54B 7.37B 319B
Net income -1.43B -1.59B -1.33B -1.2B -2.27B -152B -2.29B -15.96B -6.25B -78.53B -5.98B -5.85B -253B -1.31B -1.47B -1.22B -1.11B -2.09B -140B -2.11B -14.71B -5.76B -72.36B -5.51B -5.39B -233B
Net Debt -11.09B -12.39B -10.34B -9.38B -17.69B -1,184B -17.8B -124B -48.63B -611B -46.53B -45.5B -1,967B -9.68B -10.81B -9.02B -8.18B -15.43B -1,033B -15.53B -108B -42.44B -533B -40.61B -39.71B -1,716B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-10-12 US$95.84 -1.16% 1,276,959
26-10-09 US$96.96 +5.32% 1,320,484
26-10-08 US$92.06 -3.35% 1,206,706
26-10-07 US$95.25 -0.50% 828,075
26-10-06 US$95.73 -1.96% 899,389
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
85.80EUR
Average target price
103.73EUR
Spread / Average Target
+20.90%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE
  1. Stock Market
  2. Stocks
  3. BNTX Stock